Important Safety Information
TRILURON™ is contraindicated in patients with known hypersensitivity to hyaluronate preparations or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of TRILURON™ have not been established in pregnant women, nursing mothers, children, use in other joints, or concomitantly with other intra-articular (IA) injections. The effectiveness of a single treatment cycle of less than 3 injections has not been established.
Anaphylactoid and allergic reactions have been reported with this product. Transient increases in inflammation in the injected knee following TRILURON™ injection in some patients with inflammatory arthritis. Common adverse events include joint effusion/swelling/pain, injection site pain/hematoma, local skin reactions (rash, ecchymosis) and injection site warmth. Usually, local adverse events are transient and disappear spontaneously within a few days of resting the affected joint and/or applying ice locally. See package insert for full warnings, precautions and adverse events for more detail.
Please see Full Prescribing Information.